Abstract accepted at EHA2023 describing the potential for BTK degradation to overcome identified BTK resistance mutations in comparison to covalent and non-covalent BTK inhibitors.
Abstract accepted at EHA2023 outlining the results of an interim analysis of an ongoing study evaluating the use of BTKi in combination with established therapies in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Abstract accepted at EHA2023 presenting an updated analysis of a Phase 2 study evaluating the efficacy and safety of a BTKi in combination with an anti-CD20 monoclonal antibody in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

Chat with BeiGene